These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 11251188)

  • 21. Plasminogen activators and plasminogen activator inhibitors in neural development.
    Seeds NW; Verrall S; Friedman G; Hayden S; Gadotti D; Haffke S; Christensen K; Gardner B; McGuire P; Krystosek A
    Ann N Y Acad Sci; 1992 Dec; 667():32-40. PubMed ID: 1309053
    [No Abstract]   [Full Text] [Related]  

  • 22. Specificity of the suppression of metastatic phenotype by tyrosine and phenylalanine restriction.
    Elstad CA; Meadows GG; Abdallah RM
    Clin Exp Metastasis; 1990; 8(5):393-416. PubMed ID: 2202533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific amino acid dependency regulates the cellular behavior of melanoma.
    Fu YM; Meadows GG
    J Nutr; 2007 Jun; 137(6 Suppl 1):1591S-1596S; discussion 1597S-1598S. PubMed ID: 17513432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasminogen/plasminogen activator and growth factor activation.
    Rifkin DB; Gleizes PE; Harpel J; Nunes I; Munger J; Mazzieri R; Noguera I
    Ciba Found Symp; 1997; 212():105-15; discussion 116-8. PubMed ID: 9524766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased tissue plasminogen activator and increased plasminogen activator inhibitors and increased activator protein-1 and specific promoter 1 are associated with inhibition of invasion in human A375 melanoma deprived of tyrosine and phenylalanine.
    Pelayo BA; Fu YM; Meadows GG
    Int J Oncol; 2001 Apr; 18(4):877-83. PubMed ID: 11251188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Placenta accreta: epidemiology, molecular mechanism (hypothesis) and some clinical remarks].
    Uszyński W; Uszyński M
    Ginekol Pol; 2004 Dec; 75(12):971-8. PubMed ID: 15751221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasminogen activators and their inhibitors in arthritic disease.
    Hamilton JA; Campbell IK; Wojta J; Cheung D
    Ann N Y Acad Sci; 1992 Dec; 667():87-100. PubMed ID: 1309075
    [No Abstract]   [Full Text] [Related]  

  • 28. Regulation of the pericellular activation of plasminogen and its role in tissue-destructive processes.
    Vaheri A; Bizik J; Salonen EM; Tapiovaara H; Sirén V; Myöhänen H; Stephens RW
    Acta Ophthalmol Suppl (1985); 1992; (202):34-41. PubMed ID: 1322009
    [No Abstract]   [Full Text] [Related]  

  • 29. Plasminogen activation at the cell surface-matrix interface.
    Vaheri A; Stephens RW; Salonen EM; Pöllänen J; Tapiovaara H
    Cell Differ Dev; 1990 Dec; 32(3):255-62. PubMed ID: 2151565
    [No Abstract]   [Full Text] [Related]  

  • 30. The plasminogen activation system in melanoma cell lines and in melanocytic lesions.
    de Vries TJ; van Muijen GN; Ruiter DJ
    Melanoma Res; 1996 Apr; 6(2):79-88. PubMed ID: 8791264
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.